
1. Malar J. 2020 Jan 21;19(1):37. doi: 10.1186/s12936-020-3126-y.

Late clinical failure associated with cytochrome b codon 268 mutation during
treatment of falciparum malaria with atovaquone-proguanil in traveller returning 
from Congo.

Massamba L(1), Madamet M(2)(3)(4)(5), Benoit N(2)(3)(4)(5), Chevalier A(1), Fonta
I(2)(3)(4)(5), Mondain V(6), Jeandel PY(7), Amalvict R(2)(3)(4)(5), Delaunay
P(1)(8), Mosnier J(2)(3)(4)(5), Marty P(1)(9), Pomares C(1)(9), Pradines
B(10)(11)(12)(13).

Author information: 
(1)Parasitologie Mycologie, Centre Hospitalo-Universitaire de Nice, Université de
la Côte d'Azur, Nice, France.
(2)Unité Parasitologie et entomologie, Département de Microbiologie et de
maladies infectieuses, Institut de recherche biomédicale des armées, Marseille,
France.
(3)Aix Marseille Université, IRD, SSA, AP-HM, VITROME, Marseille, France.
(4)IHU Méditerranée Infection, Marseille, France.
(5)Centre national de référence du Paludisme, Marseille, France.
(6)Infectiologie, Centre Hospitalo-Universitaire de Nice, Université de la Côte
d'Azur, Nice, France.
(7)Service de Médecine Interne, Centre Hospitalier Universitaire de Nice, Nice,
France.
(8)MIVEGEC, UMR IRD 224-CNRS 5290-Université de Montpellier, Montpellier, France.
(9)INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, Faculté de
Médecine, Virulence microbienne et signalisation inflammatoire, Nice, France.
(10)Unité Parasitologie et entomologie, Département de Microbiologie et de
maladies infectieuses, Institut de recherche biomédicale des armées, Marseille,
France. bruno.pradines@gmail.com.
(11)Aix Marseille Université, IRD, SSA, AP-HM, VITROME, Marseille, France.
bruno.pradines@gmail.com.
(12)IHU Méditerranée Infection, Marseille, France. bruno.pradines@gmail.com.
(13)Centre national de référence du Paludisme, Marseille, France.
bruno.pradines@gmail.com.

BACKGROUND: The drug combination atovaquone-proguanil, is recommended for
treatment of uncomplicated falciparum malaria in France. Despite high efficacy,
atovaquone-proguanil treatment failures have been reported. Resistance to
cycloguanil, the active metabolite of proguanil, is conferred by multiple
mutations in the Plasmodium falciparum dihydrofolate reductase (pfdhfr) and
resistance to atovaquone by single mutation on codon 268 of the cytochrome b gene
(pfcytb).
CASE PRESENTATION: A 47-year-old female, native from Congo and resident in
France, was admitted in hospital for uncomplicated falciparum malaria with
parasitaemia of 0.5%, after travelling in Congo (Brazzaville and Pointe Noire).
She was treated with atovaquone-proguanil (250 mg/100 mg) 4 tablets daily for 3
consecutive days. On day 5 after admission she was released home. However, many
weeks after this episode, without having left France, she again experienced fever
and intense weakness. On day 39 after the beginning of treatment, she consulted
for fever, arthralgia, myalgia, photophobia, and blurred vision. She was
hospitalized for uncomplicated falciparum malaria with a parasitaemia of 0.375%
and treated effectively by piperaquine-artenimol (320 mg/40 mg) 3 tablets daily
for 3 consecutive days. Resistance to atovaquone-proguanil was suspected. The
Y268C mutation was detected in all of the isolates tested (D39, D42, D47). The
genotyping of the pfdhfr gene showed a triple mutation (N51I, C59R, S108N)
involved in cycloguanil resistance.
CONCLUSION: This is the first observation of a late clinical failure of
atovaquone-proguanil treatment of P. falciparum uncomplicated malaria associated 
with pfcytb 268 mutation in a traveller returning from Congo. These data confirm 
that the Y268C mutation is associated with delayed recrudescence 4 weeks or more 
after initial treatment. Although atovaquone-proguanil treatment failures remain 
rare, an increased surveillance is required. It is essential to declare and
publish all well-documented cases of treatment failures because it is the only
way to evaluate the level of resistance to atovaquone.

DOI: 10.1186/s12936-020-3126-y 
PMCID: PMC6975030
PMID: 31964401  [Indexed for MEDLINE]

